| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453888 | Lung Cancer | 2018 | 9 Pages |
Abstract
BM is associated with substantial economic burden. Alectinib was estimated to reduce BM-related costs by preventing or delaying the occurrence of BM compared to crizotinib.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
C. Burudpakdee, W. Wong, A. Seetasith, F.A. Corvino, W. Yeh, M. Gubens,